GSA Capital Partners LLP Raises Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

GSA Capital Partners LLP raised its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 65.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 35,813 shares of the medical device company’s stock after buying an additional 14,194 shares during the period. GSA Capital Partners LLP owned about 0.07% of AtriCure worth $1,089,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of AtriCure in the fourth quarter worth approximately $103,000. Virtu Financial LLC purchased a new stake in shares of AtriCure in the 4th quarter worth $213,000. Victory Capital Management Inc. raised its holdings in AtriCure by 22.9% in the 4th quarter. Victory Capital Management Inc. now owns 6,202 shares of the medical device company’s stock worth $221,000 after purchasing an additional 1,155 shares during the period. Aigen Investment Management LP raised its holdings in AtriCure by 24.0% in the 4th quarter. Aigen Investment Management LP now owns 7,136 shares of the medical device company’s stock worth $255,000 after purchasing an additional 1,383 shares during the period. Finally, Diversify Advisory Services LLC purchased a new position in AtriCure during the first quarter valued at $258,000. Institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on ATRC shares. Needham & Company LLC restated a “buy” rating and issued a $40.00 price target on shares of AtriCure in a research report on Monday. StockNews.com cut shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Canaccord Genuity Group dropped their price target on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Oppenheimer upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research report on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. lowered their target price on shares of AtriCure from $42.00 to $34.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and an average price target of $49.78.

Insider Activity at AtriCure

In other AtriCure news, insider Salvatore Privitera acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 30th. The stock was acquired at an average cost of $22.25 per share, with a total value of $111,250.00. Following the purchase, the insider now directly owns 103,290 shares of the company’s stock, valued at approximately $2,298,202.50. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other AtriCure news, insider Salvatore Privitera purchased 5,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average price of $22.25 per share, with a total value of $111,250.00. Following the acquisition, the insider now owns 103,290 shares in the company, valued at $2,298,202.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total value of $36,135.00. Following the sale, the insider now directly owns 71,284 shares in the company, valued at $1,717,231.56. The disclosure for this sale can be found here. 3.20% of the stock is owned by insiders.

AtriCure Price Performance

Shares of AtriCure stock traded down $0.01 during trading on Wednesday, reaching $22.23. 172,583 shares of the stock traded hands, compared to its average volume of 740,802. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.00 and a quick ratio of 2.83. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -27.80 and a beta of 1.44. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $59.61. The business has a fifty day simple moving average of $22.26 and a two-hundred day simple moving average of $28.29.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $108.90 million during the quarter, compared to the consensus estimate of $106.86 million. AtriCure had a negative return on equity of 7.85% and a negative net margin of 8.98%. The business’s revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.23) EPS. Sell-side analysts expect that AtriCure, Inc. will post -0.75 EPS for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.